Adamis Pharmaceuticals Corp - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ADMP Nasdaq 2834 http://www.adamispharmaceuticals.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Adamis Pharmaceuticals Corp

Adamis Appoints Vickie Reed to Board of Directors - May 26th, 2022 8:05 pm
Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth - May 18th, 2022 9:00 pm
Adamis Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update - May 16th, 2022 8:35 pm
Adamis Pharmaceuticals Schedules First Quarter 2022 Financial Results Conference Call and Business Update - May 9th, 2022 9:56 pm
5 Winning Stocks to Land on the Overlooked Rising P/E Trick - May 9th, 2022 11:17 am
Adamis Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Corporate Update - Mar 31st, 2022 8:49 pm
US WorldMeds and Adamis Pharmaceuticals Announce U.S. Launch of ZIMHI™ Naloxone Product - Mar 31st, 2022 8:14 pm
Acutus Medical, Inc. (AFIB) Reports Q4 Loss, Tops Revenue Estimates - Mar 30th, 2022 9:15 pm
Infinity Pharmaceuticals (INFI) Reports Q4 Loss, Tops Revenue Estimates - Mar 30th, 2022 12:15 am
Ayala Pharmaceuticals, Inc. (AYLA) Reports Q4 Loss, Tops Revenue Estimates - Mar 28th, 2022 9:25 pm
Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call and Business Update - Mar 24th, 2022 11:30 am
Adamis Pharmaceuticals Announces Results of Tempol in Omicron Virus Challenge in Hamster Model - Mar 22nd, 2022 11:30 am
Adamis Pharmaceuticals Corporation Issues Nationwide Voluntary Recall of SYMJEPI® (epinephrine) Injection for Potential Manufacturing Defect - Mar 21st, 2022 8:05 pm
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19 - Mar 14th, 2022 12:17 pm
Adamis Pharmaceuticals Announces Retirement of Richard C. Williams, Chairman of the Board - Mar 4th, 2022 12:30 pm
Adamis Pharmaceuticals’ Clinical Study Assessing Tempol for the Treatment of COVID-19 Surpasses Enrollment Expectations - Feb 28th, 2022 12:30 pm
Adamis Announces Inducement Option Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 18th, 2022 9:05 pm
Adamis Pharmaceuticals Provides Enrollment Update of Subjects in Phase 2/3 Study of Tempol for the Treatment of COVID-19 - Feb 7th, 2022 2:17 pm
Adamis Pharmaceuticals Submits Fast Track Application to FDA for Tempol for the Treatment and Prevention of COVID-19 - Jan 10th, 2022 12:30 pm
Is the Options Market Predicting a Spike in Adamis Pharmaceuticals (ADMP) Stock? - Dec 20th, 2021 3:00 pm